Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.30
+1.80 (4.68%)
Jun 18, 2026, 2:58 PM CST
Market Cap1.72B +0.9%
Revenue (ttm)1.21M -28.5%
Net Income-97.47M
EPS-2.26
Shares Out 42.60M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume798,497
Open38.50
Previous Close38.50
Day's Range38.35 - 41.50
52-Week Range29.25 - 57.00
Beta0.37
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 22
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2025, TPEX:7427's revenue was 1.21 million, a decrease of -28.49% compared to the previous year's 1.69 million. Losses were -97.47 million, -7.10% less than in 2024.

Financial Statements